Abstract Library

#2291 Somatostatin Analogs and mTOR Inhibitors as Radioprotectors or Radiosensitizers in Neuroendocrine Tumor Cells

Introduction: Neuroendocrine tumors (NETs) express somatostatin receptors that are currently utilized for diagnostic and therapeutic approaches. For peptide receptor radionuclide therapy (PRRT), somatostatin analogs are coupled to radionuclides like 90Y or 177Lu, which after injection are bound and taken up specifically by NETs. One hypothesis potentially explaining the discrepancies between expected result and observed outcome of PRRT might be that somatostatin analogs induce a G1 arrest in NET cells, thereby rendering them radioresistant.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Grötzinger C

Authors: Grötzinger C, Exner S, Prasad V, Erdmann S, Wiedenmann B,

Keywords: PRRT,

#1506 Somatostatin Analogs and mTOR Inhibitors as Radioprotectors or Radiosensitizers in Neuroendocrine Tumor Cells

Introduction: PRRT can deliver radiation doses of up to 250 Gy to the tumors. Nevertheless, complete remission is extremely rare, compared to similar radiotherapies for thyroid cancer and non-Hodgkin lymphoma.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Exner S, Erdmann S, Wiedenmann B, Prasad V, Grötzinger C,

Keywords: PRRT,